O2 (Telefónica UK) Chooses MDS Global to Enhance Direct Partner Capabilities with New Insight Portal
2.10.2019 11:00:00 EEST | Business Wire | Press release
MDS Global Ltd, a leading BSS-as-a-Service provider and O2 (Telefónica UK), have developed and implemented a new Partner Insight Portal – providing O2’s Direct Partners with focused customer and business intelligence. The data-rich portal aims to improve customer service and facilitate bespoke billing and information for sales acquisition.
The O2 Direct Partner Network is made up of a small number of providers from across the UK, chosen by O2 to work with business customers of all sizes on the company’s behalf and to help deliver brilliant digital experiences to business end users.
Until recently, Direct Partners could only view billing information by requesting it through O2’s call centre. The web-based MDS Global system makes integrated analytics instantly accessible, through a secure, and easy-to-use web portal. It can be used by business partner call centre operatives and their sales teams to check the status of service, requests, complaints, sales, and billing. The more accurate real-time data, (which answers questions such as how services are being used, identifies areas of profit and loss, and profiles customers for better sales targeting) will improve call handling, and customer satisfaction scores.
Equally important, the Portal enables information sharing with partners, whilst ensuring customer confidentiality at all times. O2 can securely configure the Partner Insight Portal so that the stored data can be filtered and tailored for a specific business partner, keeping irrelevant or private customer information hidden and adhering to GDPR rules.
Jason Phillips, Head of Partner Sales at O2, said, "At O2, we have a customer-first, mobile-led approach. While we have the highest expectations of our partners in delivering world-class customer experience, it is up to us to make sure they have the information they need to do this. Our new Insight Portal, supplied by MDS Global, is designed to have a positive impact on customer retention. It provides us and our partners with more comprehensive customer and business information so we can offer the highest levels of service, every time."
Chris Ruddle, Finance Director at Welcomm – an O2 Direct Partner – said: “I am delighted that Welcomm was amongst the first partners to have access to O2’s new Partner Insight Portal. It will not only improve the efficiency of our customer care team in dealing with customer queries, but will also provide us with up-to-date information we need to take our customer support to the next level.”
John Roulston, Sales Director at Barclays, adds: “O2’s Insight Portal launch is something we have been excited about for some time. From sales to service, it will change every aspect of how we drive experience for our customers. Churn, service delivery and revenue will all benefit from this excellent innovation and investment from O2. I’m certain this will be the main catalyst for growth over the next few years. We look forward to embracing it long term.”
Gary Bunney, CEO at MDS Global, said: "The Portal will transform the customer and business partner experience. We expect it to decrease churn through improved customer visibility and to help direct partners manage profitability."
About Telefónica UK(O2)
O2 is a mobile network operator and the principal commercial brand of Telefónica UK Limited, which is part of the global telecommunications group Telefónica S.A, headquartered in Spain and operating in Europe, and North, Central and South America.
Telefónica UK Limited is registered in England and Wales. Registration number: 1743099.
About MDS Global
MDS Global, based in the UK, is a leading BSS-as-a-Service provider of VNO, B2B and IoT solutions.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191002005018/en/
Contact information
Martine Naughton
martine.naughton@mdsglobal.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Brenus Pharma Presented New Preclinical and Early Clinical Data in Colorectal Cancer During AACR Immuno-Oncology Conference 202619.2.2026 09:50:00 EET | Press release
Brenus Pharma, a clinical-stage biotechnology company pioneering in vivo “off-the-shelf” immunotherapies, announced the selection of an abstract for a poster presentation at the American Association for Cancer Research Immuno-Oncology (AACRIO) annual conference (February 18-21, 2026), in Los Angeles. The poster showcases new preclinical data and early clinical insights from the company's lead candidate, STC-1010, supporting it as a promising therapeutic option for MSS, immune-cold colorectal cancer (CRC)—a major unmet clinical need. In a syngeneic CT26 model, murine STC-1010 significantly inhibits tumor growth and extends survival by 40%. New mechanistic datas reveal expansion of CD4⁺ and CD8⁺ T cells in draining lymph nodes alongside a significant humoral response compared to control, demonstrating coordinated cellular and humoral immune activation in vivo. Other findings show that dendritic cells efficiently capture STC-1010, leading to their activation as demonstrated by transcripto
ENHERTU ® Type II Variation Application Validated in the EU as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer19.2.2026 09:30:00 EET | Press release
The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for ENHERTU® (trastuzumab deruxtecan) as a monotherapy for adult patients with HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer who have residual invasive disease after neoadjuvant HER2 targeted treatment. ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Products for Human Use (CHMP). The application is based on data from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. In the trial, ENHERTU demo
NHOA Energy Advances Delivery of the 51 MWh Broni Battery for Neoen in Italy19.2.2026 09:00:00 EET | Press release
NHOA Energy, global provider of utility-scale energy storage systems, is advancing the construction of the Broni Battery, a 10 MW/51 MWh project located in Broni (Pavia), Italy, executed for Neoen, one of the world’s leading independent producers of renewable energy. Civil works at the site are currently underway and advancing on schedule, with commissioning activities planned to start in late spring 2026. Once operational, the Broni Battery will provide essential flexibility services to the Italian electricity system, supporting grid stability and reliability as renewable energy penetration continues to increase. The project represents Neoen’s first battery storage asset in Italy and marks a strategic step in the company’s expansion, as it continues to grow its battery storage portfolio in key markets worldwide to support power system flexibility. The Broni Battery further strengthens NHOA Energy’s long-term commitment to the Italian market, where the company has deep industrial roots
Compass Pathways Announces Pricing of $150 Million Public Offering19.2.2026 03:18:00 EET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the pricing of its public offering of 17,500,000 American Depositary Shares (“ADSs”) at a public offering price of $8.00 per ADS, each representing one ordinary share, and in lieu of ADSs, to certain institutional investors, pre-funded warrants to purchase up to 1,250,000 ADSs at a public offering price of $7.9999 per pre-funded warrant. In addition, Compass Pathways has granted the underwriters a 30-day option to purchase up to an additional 2,812,500 ADSs at the public offering price, less the underwriting discounts and commissions. All of the securities are to be sold by Compass Pathways. The offering is expected to close on or about February 20, 2026, subject to the satisfaction of customary closing conditions. The gross proceeds to Compass Pathways from the offering, before deducting underwriting discounts and commissions and other est
Perpetual Atomics Ltd, QSA Europe, QSA Global and Reef Origin to Collaborate on Building Radioisotope Power Systems in Europe18.2.2026 17:44:00 EET | Press release
Perpetual Atomics Ltd, QSA Europe (a trading name of Loma Systems s.r.o.), QSA Global, Inc., and Reef Origin signed an MOU in Prague to collaborate on the industrialized production of radioisotope power systems in Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260218036211/en/ Teams from Perpetual Atomics & QSA Global (USA and Czechia) at the facilities in Czechia This MOU builds on the existing collaboration between QSA Global, Inc. and Perpetual Atomics Ltd by expanding and strengthening the capacity and capability to produce radioisotope power systems in Europe. The key partnership with QSA Europe provides access to existing facilities, capabilities, knowledge, and know-how for the storage, handling, and distribution of commercial radioisotope systems for terrestrial applications. This capability is directly transferable to radioisotope power technologies for space. Radioisotope and nuclear power technologies are
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom